Cushing disease is a relatively rare cause of Cushing syndrome secondary to a hyperfunctioning pituitary adenoma. In addition to signs and symptoms of hypercortisolism, Cushing disease may present with diverse otolaryngic manifestations, which may guide diagnosis and management. We performed a retrospective chart review of patients who were found to have Cushing disease and who underwent transnasal transsphenoidal surgery for pituitary adenomas between January 1, 2007, and July 1, 2014, at a tertiary academic medical center. There were 37 consecutive patients in this series with Cushing disease caused by a pituitary adenoma. Fifteen (41%) patients complained of visual changes. Five (14%) patients suffered from obstructive sleep apnea. Four (11%) patients had thyroid disease. Other symptoms included hearing loss, vertigo, tinnitus, epistaxis, dysphagia, and salivary gland swelling. Although Cushing disease traditionally presents with classic "Cushingoid" systemic features, it also may present with various otolaryngic manifestations. A thorough workup by otolaryngologists is critical in the comprehensive management of these patients.
Introduction
Cushing disease (CD) results from excessive adrenocorticotropic hormone (ACTH) secretion by a hyperfunctioning pituitary gland tumor leading to uncontrolled adrenal gland stimulation and cortisol secretion. It is the most common cause of Cushing syndrome, with an incidence of 10 to 15 persons per million and accounting for 60 to 70% of all cases. 1 So-called "Cushingoid" patients afflicted with Cushing syndrome have abnormal fat metabolism, leading to weight gain, buffalo hump formation, moon facies, and truncal obesity; skin changes, such as abdominal striae and poor wound healing; hirsutism and virilization; and cardiovascular abnormalities, such as diastolic hypertension.
Treatment of CD is predominantly surgical-namely, removal of the pituitary adenoma-with medical therapy being reserved for poor surgical candidates. 2 Medical therapy for CD includes somatostatin receptor analogs and cortisol inhibitors, with radiation therapy also considered for select nonsurgical candidates or for postoperative treatment of patients with residual tumor. 3 The success rate of transnasal transsphenoidal (TNTS) resection of CD pituitary tumors is as high as 70 to 80% for both primary and revision cases. 2, 4 As a systemic disease, CD also may produce symptoms in the head and neck, although these manifestations have not been well studied. The purpose of this study was to (1) review the otolaryngic manifestations of CD in patients undergoing TNTS resection of pituitary adenoma, and (2) compare preoperative and postoperative Sinonasal Outcome Test 22 (SNOT-22) scores in these patients.
Patients and methods
Institutional Review Board approval was obtained for this study.
Inclusion criteria included a diagnosis of an ACTH-secreting pituitary adenoma treated with TNTS surgery by a skull base surgery team (one otolaryngologist and one neurosurgeon) between January 2007 and July 2014. Patient charts were retrospectively reviewed for otolaryngic symptoms at initial evaluation. Summary descriptive statistics were calculated.
An additional subset of patients who completed preoperative and/or postoperative SNOT-22 questionnaires was identified. Although the SNOT-22 questionnaire, a validated outcomes instrument, is geared toward assessing quality of life related to rhinologic symptoms, 5 it may also be applied more broadly to other otolaryngic issues. 6 Differences between the preoperative and postoperative SNOT-22 questionnaire scores were compared using a Student t test with a significance level of 0.05. 
Results
Thirty-seven patients were diagnosed with CD and treated with TNTS surgery. Their mean age was 39 years (range, 12 to 65 years). Of these patients, 7 (19%) were male and 30 (81%) were female. Mean body mass index was 32.2 (range, 17.4 to 50.8).
The American Society of Anesthesiologists Physical Status Classification scale was reviewed for each patient, with 14 (38%) being class 2 and 23 (62%) being class 3. All patients underwent a TNTS approach to the sella turcica with tumor resection via a pseudocapsular dissection technique (figure); none of the patients required any additional endoscopic sinus, septal, or turbinate surgery.
The table illustrates the various head and neck manifestations seen in the study population. The most common complaint was visual changes, which was reported by 16 (43%) patients. Five (14%) patients had a diagnosis of obstructive sleep apnea (OSA). Four (11%) patients had complaints of dry eyes, and another 4 also had a diagnosis of hypothyroidism (confirmed both clinically and on laboratory analysis). Other otolaryngic complaints included hearing loss, tinnitus, epistaxis, chronic rhinosinusitis (clinical diagnosis), dysphagia, and salivary gland enlargement.
A subset of CD patients completed preoperative and/ or postoperative SNOT-22 questionnaires (n = 6 and 10, respectively); all were female. The mean length of follow-up for postoperative SNOT-22 evaluation was 65 days (range: 8 to 356 days). The mean preoperative SNOT-22 score was 28.0 ± 3.2 (range: 3 to 56), and the mean postoperative SNOT-22 score was 29.9 ± 1.6 (range: 12 to 59); the difference was not statistically significant (p = 0.56).
Discussion
CD, although traditionally thought of as producing classical "Cushingoid" features, is also associated with other clinical manifestations, many of which occur in the head and neck. These signs and symptoms include visual changes, sleep apnea, hearing changes, and rhinologic complaints, among others. Therefore, the otolaryngologist, as part of the skull base interdisciplinary team, is tasked to become cognizant of these features and to apply them in the appropriate diagnosis and management of CD. To the best of our knowledge, this is the first study to identify the prevalence of these head and neck manifestations in CD.
Visual changes appeared to be most prevalent among CD patients with head and neck manifestations. As most CD adenomas are relatively small but hyperfunctioning, visual changes are less likely to be a result of direct pituitary compression (i.e., as in the case of a large, nonfunctioning pituitary adenoma elevating the optic chiasma), but rather from the ocular sequelae of hypercortisolism. For instance, patients with CD tend to be hyperglycemic and exhibit insulin resistance, 7 and as such are at higher risk for developing diabetic retinopathy 8 and cataracts. For this reason, patients should be counseled preoperatively regarding continued optometric and ophthalmologic follow-up even after successful tumor removal, as surgery only eliminates the source of the disease but may not reverse hypercortisolism-related ocular injury.
Truncal obesity and weight gain are hallmarks of Cushing syndrome, and these patients naturally are at an elevated risk of developing OSA. 9 OSA poses a special challenge in these patients as they also often have concurrent cardiovascular disease, making their overall surgical risk much higher than average. Hypothyroidism in CD is speculated to be related to anterior pituitary compression leading to central hypofunction. Niepomniszcze et al found that subclinical hypothyroidism is present in 23.7% of patients with Cushing syndrome, which is higher than the current study's finding of 11%. 10 Many of the other otolaryngic In at least one study, a "normal" SNOT-22 score was considered to be anything less than 7. 11 The current study population had an average SNOT-22 score around 30, indicating that patients with CD have at least some degree of measurable otolaryngic complaints. Additional quality-of-life and outcomes assessment tools, such as the Short Form Health Survey 36-item questionnaire, may provide further information on this finding.
The current study has several limitations. Although average SNOT-22 scores could be calculated, the small sample size ultimately prevents us from drawing statistically robust conclusions from the data. Also, the length of follow-up was quite heterogenous because of the nonstandardized timing of follow-up appointments. Future studies will require more systematic planning, including power analysis and predefined time points to assess outcomes.
Conclusion
CD is a rare disease, and patients with CD may present with a variety of otolaryngic complaints. As part of the skull base team, the otolaryngologist must be aware of these manifestations to provide optimal care in the diagnosis and management of the disease.
